8-K: Biotricity Inc. Faces Nasdaq Delisting After Failing to Meet Market Value Requirement

Biotricity Inc. received a delisting notice from Nasdaq after failing to maintain the minimum market value of listed securities, but intends to appeal the decision.

Summary

• Biotricity Inc. received a deficiency letter from Nasdaq on August 4, 2023, because its Market Value of Listed Securities (MVLS) fell below the required $35 million.
• Nasdaq granted Biotricity until January 29, 2024, to regain compliance with the MVLS requirement.
• On January 30, 2024, Biotricity received a delisting determination letter from Nasdaq, stating that the company did not meet the MVLS requirement by the deadline.
• Trading of Biotricity's common stock on the Nasdaq Capital Market is scheduled to be suspended on February 8, 2024, unless the company appeals.
• Biotricity intends to appeal the delisting decision and present a plan to regain compliance with the MVLS requirement.

Sentiment

Score: 3

Explanation: The document indicates a significant negative event (delisting notice) despite the company's intention to appeal. The overall tone is concerning for investors.

Positives

• Biotricity intends to appeal the delisting decision, which will temporarily prevent the suspension of trading.
• The company plans to present a plan to regain compliance with the MVLS requirement during the appeal hearing.

Negatives

• Biotricity failed to maintain the minimum $35 million Market Value of Listed Securities (MVLS).
• The company received a delisting determination letter from Nasdaq.
• Trading of Biotricity's stock is scheduled to be suspended on February 8, 2024, if the appeal is unsuccessful.

Risks

• There is a risk that Biotricity's appeal will be unsuccessful, leading to the delisting of its stock from the Nasdaq Capital Market.
• Failure to regain compliance with the MVLS requirement could negatively impact investor confidence and the company's ability to raise capital.
• The delisting could lead to reduced liquidity and potentially lower valuation of the company's stock.

Future Outlook

Biotricity intends to appeal the delisting decision and present a plan to regain compliance with the MVLS requirement, but the outcome is uncertain.

Management Comments

• The company intends to submit a hearing request to the Nasdaq Hearings Panel to appeal the Staff's delisting determination.
• At the hearing, the Company intends to present a plan to regain compliance with the MVLS Requirement.

Industry Context

Delisting notices are not uncommon for companies that fail to meet the minimum listing requirements of exchanges like Nasdaq, reflecting the competitive nature of the market and the importance of maintaining financial health.

Comparison to Industry Standards

• Many companies on the Nasdaq Capital Market struggle to maintain the minimum MVLS requirement, especially during periods of market volatility.
• Companies that fail to meet the MVLS requirement are often given a grace period to regain compliance, similar to Biotricity's situation.
• The delisting process is a standard procedure for companies that do not meet the listing requirements, and the appeal process is a common recourse.

Stakeholder Impact

• Shareholders face the risk of delisting and potential loss of value.
• Employees may experience uncertainty due to the company's financial challenges.
• Customers and suppliers may be concerned about the company's long-term viability.

Next Steps

• Biotricity will submit a hearing request to the Nasdaq Hearings Panel.
• The company will present a plan to regain compliance with the MVLS requirement at the hearing.

Key Dates

Keywords

delisting, Nasdaq, MVLS, market value, compliance, appeal, Biotricity, stock suspension